Health TrialsbyHealthPanel

Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

ConditionsNeurodegenerative DiseasesParkinson DiseaseSynucleinopathiesLewy Body DiseaseMultiple System AtrophyTauopathiesAlzheimer DiseaseCorticobasal DegenerationSupranuclear Palsy, ProgressiveAtypical ParkinsonismTDP-43 ProteinopathiesAmyotrophic Lateral SclerosisFrontotemporal Lobar DegenerationMovement DisordersCognitive ImpairmentDementiaIron OverloadNeurodegeneration With Brain Iron Accumulation (NBIA)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age10+
SponsorCasa di Cura San Raffaele Cassino

About this trial

MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders

Patients with diagnosis of Parkinson's Disease

Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank

Diagnosis of Movement Disorder not related to Parkinson's Disease

Disqualifiers

There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.

Trial population

Patients with Neurodegerative Diseases

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Observation

    Other intervention

    In MARKERS-NDD up to 600 participants will be enrolled and followed longitudinally once identified, over the course of 1-10 years

Treatment groups

600 Participants
are divided into 2 treatment groups
Group A: Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders1 intervention
Group B: Patients affected by cognitive impairment (CI) and dementia1 intervention

Trial outcomes

Primary outcomes

1

To monitor and predict the course of neurodegenerative diseases through the study of clinical markers and the creation of AI-models

To identify markers of neurodegenerative disease progression for use in clinical monitoring

Time frame
Baseline to 120 months

Secondary outcomes

1

To predict the risk to develop neurodegenerative diseases through the study of clinical markers and the creation of AI-models

To identify markers of neurodegenerative disease for use in early clinical diagnosis

Time frame
Baseline to 120 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Casa di Cura San Raffaele Cassino

Lead sponsor

IRCCS San Raffaele Roma

Collaborator

San Raffaele Telematic University

Collaborator

University of Urbino "Carlo Bo"

Collaborator

University of Cassino and Southern Lazio

Collaborator

University of Roma La Sapienza

Collaborator

Politecnico di Milano

Collaborator

Source ClinicalTrials.gov
Apply now